The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.
RPRD will expand the availability of its PGx testing services to South Korea, and Orient Bio will diversify its business to include precision medicine and clinical PGx.
The two firms will offer their technologies and services to patients in Hong Kong, Japan, and Macau to improve drug dosing and prescriptions.
The deals will expand the availability of Admera's pharmacogenomics testing services to markets including Singapore, Hong Kong, Korea, and Taiwan.
A new company, Wamberg Genomic Advisors, launched last week, hoping to provide a conduit to genomic testing through the insurance and employee benefit marketplaces.
The company joins others in a still-controversial setting, hoping to market its test to help guide the prescription of narcotic pain medications.
NBC News reports that pharmacogenomics can help match people with depression to drugs that may work best for them.
The RightMed test covers 22 genes in which variants are known to contribute to the effectiveness or safety of more than 340 drugs for more than 20 indications.
The test covers 22 genes in which variants are known to contribute to the effectiveness or safety of more than 340 drugs for more than 20 indications.
The effort is already bearing fruit, as the team has been able to validate several variants known to be connected with adverse drug reactions.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.